Natasha Kyprianou Mbbs

List of Publications by Year
in descending order

126 papers	7,388 citations	47006 47 h-index	60623 81 g-index
129 all docs	129 docs citations	129 times ranked	7505 citing authors

#	Article	IF	Citations
1	Activation of Programmed Cell Death in the Rat Ventral Prostate after Castration*. Endocrinology, 1988, 122, 552-562.	2.8	651
2	Expression of Transforming Growth Factor-Î² in the Rat Ventral Prostate during Castration-Induced Programmed Cell Death. Molecular Endocrinology, 1989, 3, 1515-1522.	3.7	405
3	Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer. Cancer Research, 2010, 70, 7992-8002.	0.9	313
4	Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocrine-Related Cancer, 2008, 15, 841-849.	3.1	234
5	Role of androgens and the androgen receptor in epithelialâ€mesenchymal transition and invasion of prostate cancer cells. FASEB Journal, 2010, 24, 769-777.	0.5	198
6	Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Human Pathology, 1996, 27, 668-675.	2.0	185
7	Talin1 Promotes Tumor Invasion and Metastasis via Focal Adhesion Signaling and Anoikis Resistance. Cancer Research, 2010, 70, 1885-1895.	0.9	182
8	Identification of a Cellular Receptor for Transforming Growth Factor-Î² in Rat Ventral Prostate and Its Negative Regulation by Androgens*. Endocrinology, 1988, 123, 2124-2131.	2.8	177
9	Targeting anoikis resistance in prostate cancer metastasis. Molecular Aspects of Medicine, 2010, 31, 205-214.	6.4	146
10	INDUCTION OF PROSTATE APOPTOSIS BY DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 1998, 159, 1810-1815.	0.4	139
11	Anoikis and EMT: Lethal "Liaisons" during Cancer Progression. Critical Reviews in Oncogenesis, 2016, 21, 155-168.	0.4	139
12	Targeting caspases in cancer therapeutics. Biological Chemistry, 2013, 394, 831-843.	2.5	134
13	bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. , 1997, 70, 341-348.		127
14	alpha _{1-ADRENOCEPTOR} ANTAGONISTS TERAZOSIN AND DOXAZOSIN INDUCE PROSTATE APOPTOSIS WITHOUT AFFECTING CELL PROLIFERATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. Journal of Urology, 1999, 161, 2002-2008.	0.4	127
15	Anoikis and Survival Connections in the Tumor Microenvironment: Is There a Role in Prostate Cancer Metastasis?: Figure 1.. Cancer Research, 2005, 65, 11230-11235.	0.9	126
16	Doxazosin and Terazosin Suppress Prostate Growth by Inducing Apoptosis: Clinical Significance. Journal of Urology, 2003, 169, 1520-1525.	0.4	113
17	Down-regulation of protein and mRNA expression for transforming growth factor-Î² (TGF-Î²1) type I and type II receptors in human prostate cancer. International Journal of Cancer, 1997, 71, 573-579.	5.1	110
18	Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance. Journal of Cellular Biochemistry, 2006, 97, 18-32.	2.6	110

#	Article	IF	Citations
19	Mechanisms of Therapeutic Resistance in Prostate Cancer. Current Oncology Reports, 2017, 19, 13.	4.0	103
20	Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Research, 2002, 62, 597-602.	0.9	99
21	Prohibitin and Cofilin Are Intracellular Effectors of Transforming Growth Factor Î² Signaling in Human Prostate Cancer Cells. Cancer Research, 2006, 66, 8640-8647.	0.9	97
22	Apoptosis in prostate carcinogenesis. Cell and Tissue Research, 2000, 301, 153-162.	2.9	96
23	Profiling Prostate Cancer Therapeutic Resistance. International Journal of Molecular Sciences, 2018, 19, 904.	4.1	96
24	Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF-Î²1 and bcl-2 expression. , 1996, 69, 357-363.		94
25	Loss of Cell Cycle Regulators p27Kip1 and Cyclin E in Transitional Cell Carcinoma of the Bladder Correlates with Tumor Grade and Patient Survival. American Journal of Pathology, 1999, 155, 1129-1136.	3.8	93
26	Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. Translational Andrology and Urology, 2013, 2, 202-211.	1.4	93
27	Targeting TGF-Î² in prostate cancer: therapeutic possibilities during tumor progression. Expert Opinion on Therapeutic Targets, 2009, 13, 227-234.	3.4	90
28	Cofilin Drives Cell-Invasive and Metastatic Responses to TGF-Î² in Prostate Cancer. Cancer Research, 2014, 74, 2362-2373.	0.9	90
29	Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer. International Journal of Biological Sciences, 2014, 10, 588-595.	6.4	87
30	Live Free or Die. American Journal of Pathology, 2010, 177, 1044-1052.	3.8	85
31	Doxazosin Induces Apoptosis of Benign and Malignant Prostate Cells via a Death Receptorâ€"Mediated Pathway. Cancer Research, 2006, 66, 464-472.	0.9	84
32	Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-? expression in benign prostatic hyperplasia. Prostate, 2001, 46, 45-51.	2.3	71
33	Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer. Cancer Research, 2016, 76, 912-926.	0.9	71
34	Significance of Talin in Cancer Progression and Metastasis. International Review of Cell and Molecular Biology, 2011, 289, 117-147.	3.2	69
35	Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. Cancers, 2020, 12, 2984.	3.7	69
36	Effect of Î±1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort Study. Journal of Urology, 2007, 178, 2176-2180.	0.4	67

#	Article	IF	Citations
37	Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. British Journal of Pharmacology, 2006, 147, S144-S152.	5.4	64
38	Pharmacological Exploitation of the Î±1-Adrenoreceptor Antagonist Doxazosin to Develop a Novel Class of Antitumor Agents That Block Intracellular Protein Kinase B/Akt Activation. Journal of Medicinal Chemistry, 2004, 47, 4453-4462.	6.4	59
39	Mechanisms navigating the TGF-Î² pathway in prostate cancer. Asian Journal of Urology, 2015, 2, 11-18.	1.2	59
40	PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. Carcinogenesis, 2014, 35, 2592-2601.	2.8	58
41	Profiles of Radioresistance Mechanisms in Prostate Cancer. Critical Reviews in Oncogenesis, 2018, 23, 39-67.	0.4	58
42	Apoptosis incidence and protein expression of p53, TGF-Î² receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate1 1Accepted for publication 0, 2003.. Human Pathology, 2004, 35, 290-297.	2.0	57
43	Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. Journal of Cellular Biochemistry, 2005, 94, 374-388.	2.6	56
44	Dysfunctional Transforming Growth Factor-Î² Receptor II Accelerates Prostate Tumorigenesis in the TRAMP Mouse Model. Cancer Research, 2009, 69, 7366-7374.	0.9	54
45	Dihydrotestosterone Enhances Transforming Growth Factor-Î²-Induced Apoptosis in Hormone-Sensitive Prostate Cancer Cells*. Endocrinology, 2001, 142, 2419-2426.	2.8	53
46	Nâ€terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Molecular Oncology, 2015, 9, 628-639.	4.6	52
47	Anoikis Induction by Quinazoline Based Î±1-Adrenoceptor Antagonists in Prostate Cancer Cells: Antagonistic Effect of Bcl-2. Journal of Urology, 2003, 169, 1150-1156.	0.4	50
48	Transforming Growth Factor Beta and Prostate Cancer. , 2005, 126, 157-173.		50
49	Dysregulation of the Mitogen Granulin in Human Cancer through the miR-15/107 microRNA Gene Group. Cancer Research, 2010, 70, 9137-9142.	0.9	50
50	Novel Quinazoline-Based Compounds Impair Prostate Tumorigenesis by Targeting Tumor Vascularity. Cancer Research, 2007, 67, 11344-11352.	0.9	49
51	Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond. Journal of Steroid Biochemistry and Molecular Biology, 2017, 166, 84-90.	2.5	49
52	Combined Antitumor Effect of Suramin Plus Irradiation in Human Prostate Cancer Cells: The Role of Apoptosis. Journal of Urology, 1993, 150, 1526-1532.	0.4	46
53	Effects of Alpha1-adrenoceptor (?1-AR) antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications in prostatic disease. Prostate, 2000, 45, 42-46.	2.3	46
54	TGF-Î² signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Prostate, 2008, 68, 287-295.	2.3	46

#	Article	IF	Citations
55	TGFâ€Î² receptor I inhibitor enhances response to enzalutamide in a preâ€clinical model of advanced prostate cancer. Prostate, 2019, 79, 31-43.	2.3	46
56	Prohibitin regulates TGFâ€Î² induced apoptosis as a downstream effector of smadâ€dependent and â€independent signaling. Prostate, 2010, 70, 17-26.	2.3	44
57	Androgen regulation of epithelialâ€“mesenchymal transition in prostate tumorigenesis. Expert Review of Endocrinology and Metabolism, 2011, 6, 469-482.	2.4	44
58	Modeling Prostate Cancer in Mice: Limitations and Opportunities. Journal of Andrology, 2012, 33, 133-144.	2.0	42
59	Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene, 2005, 24, 5375-5383.	5.9	38
60	Racial differences in prostate cancer growth: Apoptosis and cell proliferation in Caucasian and African-American patients. , 2000, 42, 130-136.		37
61	Apoptotic impact of Î±₁â€blockers on prostate cancer growth: A myth or an inviting reality?. Prostate, 2004, 59, 91-100.	2.3	37
62	Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance. Journal of Cellular Biochemistry, 2008, 103, 691-708.	2.6	36
63	Anoikis Disruption of Focal Adhesion-Akt Signaling Impairs Renal Cell Carcinoma. European Urology, 2011, 59, 734-744.	1.9	36
64	Predictive value of epithelialâ€mesenchymalâ€transition (EMT) signature and PARPâ€1 in prostate cancer radioresistance. Prostate, 2017, 77, 1583-1591.	2.3	36
65	Emerging biomarkers of prostate cancer (Review). Oncology Reports, 2012, 28, 409-417.	2.6	35
66	Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. Advances in Cancer Research, 2015, 127, 123-158.	5.0	34
67	The Promise of Novel Molecular Markers in Bladder Cancer. International Journal of Molecular Sciences, 2014, 15, 23897-23908.	4.1	33
68	The role of Î±-blockers in the management of prostate cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 1279-1285.	1.8	32
69	Novel Pharmacologic Targeting of Tight Junctions and Focal Adhesions in Prostate Cancer Cells. PLoS ONE, 2014, 9, e86238.	2.5	32
70	Prostate tumor neuroendocrine differentiation via EMT: The road less traveled. Asian Journal of Urology, 2019, 6, 82-90.	1.2	32
71	Effect of permixon on human prostate cell growth: Lack of apoptotic action. Prostate, 2004, 61, 73-80.	2.3	31
72	Reduction of human prostate tumor vascularity by the ?1-adrenoceptor antagonist terazosin. Prostate, 2001, 48, 71-78.	2.3	30

#	Article	IF	Citations
73	Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy. Current Cancer Drug Targets, 2004, 4, 85-95.	1.6	27
74	Advances in the design and synthesis of prazosin derivatives over the last ten years. Expert Opinion on Therapeutic Targets, 2011, 15, 1405-1418.	3.4	27
75	Cytoskeleton targeting value in prostate cancer treatment. American Journal of Clinical and Experimental Urology, 2014, 2, 15-26.	0.4	27
76	bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-? and dihydrotestosterone in prostate cancer cells. Prostate, 2002, 53, 133-142.	2.3	26
77	Epithelialâ€"mesenchymal transition in prostatic disease. Future Oncology, 2015, 11, 3197-3206.	2.4	26
78	Aberrant TGF-Î² Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis. Endocrinology, 2017, 158, 1612-1622.	2.8	26
79	Therapeutic value of quinazoline-based compounds in prostate cancer. Anticancer Research, 2013, 33, 4695-700.	1.1	26
80	Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Prostate, 2006, 66, 1194-1202.	2.3	25
81	Personalization of prostate cancer therapy through phosphoproteomics. Nature Reviews Urology, 2018, 15, 483-497.	3.8	25
82	Dihydrotestosterone Enhances Transforming Growth Factor-Â-Induced Apoptosis in Hormone-Sensitive Prostate Cancer Cells. Endocrinology, 2001, 142, 2419-2426.	2.8	24
83	Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer. Human Pathology, 2016, 57, 68-77.	2.0	22
84	Exosomes as A Next-Generation Diagnostic and Therapeutic Tool in Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 10131.	4.1	22
85	Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells. Oncotarget, 2017, 8, 78507-78519.	1.8	21
86	Apoptosis induction by doxazosin and other quinazoline Î±1-adrenoceptor antagonists: a new mechanism for cancer treatment?. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 380, 473-477.	3.0	20
87	Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. Prostate, 1994, 25, 177-188.	2.3	18
88	Intracellular death platform stepsâ€in: Targeting prostate tumors via endoplasmic reticulum (ER) apoptosis. Prostate, 2008, 68, 1615-1623.	2.3	18
89	EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate, 2012, 72, 72-81.	2.3	18
90	Proteasomal regulation of caspase-8 in cancer cell apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 766-776.	4.9	16

#	Article	IF	Citations
91	Induction of apoptosis in the prostate by Î±1-adrenoceptor antagonists: A novel effect of â€œOldâ€•drugs. Current Urology Reports, 2000, 1, 89-96.	2.2	15
92	ASK-ing EMT not to spread cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2731-2732.	7.1	14
93	Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology, 2005, 65, 1019-1023.	1.0	13
94	Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance. International Journal of Molecular Sciences, 2021, 22, 2100.	4.1	13
95	Molecular tracing of prostate cancer lethality. Oncogene, 2020, 39, 7225-7238.	5.9	10
96	The Resilient Child: Sex-Steroid Hormones and COVID-19 Incidence in Pediatric Patients. Journal of the Endocrine Society, 2020, 4, bvaa106.	0.2	10
97	Decreased risk of bladder cancer in men treated with quinazoline-based Î±1-adrenoceptor antagonists. Gene Therapy and Molecular Biology, 2008, 12, 253-258.	1.3	10
98	Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 572.e1-572.e11.	1.6	9
99	Therapeutic challenges in renal cell carcinoma. American Journal of Clinical and Experimental Urology, 2015, 3, 77-90.	0.4	9
100	Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. Anticancer Research, 2002, 22, 1673-9.	1.1	9
101	POTENTIN VITROANTICANCER ACTIVITIES OF RING-EXPANDED (â€œFATâ€) NUCLEOSIDES CONTAINING THE IMIDAZO[4,5-E][1,3]DIAZEPINE RING SYSTEM. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 1043-1045.	1.1	8
102	Cell death under epithelialâ€"mesenchymal transition control in prostate cancer therapeutic response. International Journal of Urology, 2018, 25, 318-326.	1.0	8
103	Predictive and targeting value of IGFBP-3 in therapeutically resistant prostate cancer. American Journal of Clinical and Experimental Urology, 2019, 7, 188-202.	0.4	8
104	Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cells. , 1997, 32, 266-271.		7
105	Repurposing of Î±1-Adrenoceptor Antagonists: Impact in Renal Cancer. Cancers, 2020, 12, 2442.	3.7	7
106	Sequencing hormonal ablation and radiotherapy in prostate cancer: a molecular and therapeutic prespective (Review). Oncology Reports, 2002, 9, 1151-6.	2.6	7
107	Gene fusions find an ERG-way to tumor inflammation. Cancer Biology and Therapy, 2011, 11, 418-420.	3.4	6
108	Impact of Î±-adrenoceptor antagonists on prostate cancer development, progression and prevention. American Journal of Clinical and Experimental Urology, 2019, 7, 46-60.	0.4	5

#	Article	IF	Citations
109	Impact of Circadian Rhythms on the Development and Clinical Management of Genitourinary Cancers. Frontiers in Oncology, 2022, 12, 759153.	2.8	5
110	Molecular Signatures in Urologic Tumors. International Journal of Molecular Sciences, 2013, 14, 18421-18436.	4.1	3
111	The Fringe Benefits of Cloning Cancer. Science Translational Medicine, 2014, 6, 254fs36.	12.4	3
112	Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. Prostate, 2020, 80, 926-937.	2.3	3
113	Androgen Receptor Signaling Interactions Control Epithelialâ€"Mesenchymal Transition (EMT) in Prostate Cancer Progression. , 2013, , 227-255.		3
114	Expression patterns of epithelialâ€"mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU International, 2013, 111, 6-7.	2.5	2
115	Downâ€regulation of protein and mRNA expression for transforming growth factorâ€Î² (TGFâ€Î²1) type I and type II receptors in human prostate cancer. International Journal of Cancer, 1997, 71, 573-579.	5.1	2
116	Pathophysiology of Castration-Resistant Prostate Cancer. , 2016, , 5-22.		1
117	Adipose tissue: enabler of prostate cancer aggressive behavior. Translational Andrology and Urology, 2019, 8, S242-S245.	1.4	1
118	Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 183-198.	1.6	1
119	Induction of Prostate Apoptosis in Response to Î±1â€Adrenoceptor Antagonists: Therapeutic Significance in Benign Prostatic Hyperplasia and Prostate Cancer. Prostate Journal, 1999, 1, 73-81.	0.2	0
120	Talin1 Promotes Prostate Cancer Invasion and Metastasis via AKT Signaling and Anoikis Resistance. Nature Precedings, 2009, , .	0.1	0
121	Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelialâ€"mesenchymal transition. Expert Review of Endocrinology and Metabolism, 2013, 8, 403-416.	2.4	0
122	p27 Stands-Up-To-Cancer: UPS Nuclear Service Stops. Endocrinology, 2013, 154, 3970-3973.	2.8	0
123	Homeless Cells Escape Death and Deliver Lethal Cancer. Endocrinology, 2021, 162, .	2.8	0
124	Apoptosis and Cell Cycle Deregulation in Prostate Cancer. , 2003, , 511-549.		0
125	Nuclear spindles pave the way to metastasis. Oncotarget, 2018, 9, 12544-12545.	1.8	0
126	Prostate MRI percentage tumor involvement or â€œPIâ€RADS percentâ€• as a predictor of adverse surgical pathology. Prostate, 2022, , .	2.3	0